Eli Lilly halts new studies and exports of some medicines to Russia

Pharmaceutical firm Eli Lilly, a competitor to Novo Nordisk on the US insulin scene, says it is ethically bound to protect patients, even if they live in Russia, which is heavily sanctioned.


Eli Lilly & Co. said it has suspended investment, promotional activity and new clinical trials in Russia, and has stopped exporting nonessential medicines to the country, in response to the war in Ukraine.

The Indianapolis-based drugmaker, which is one of the world’s biggest producers of insulin, said in an emailed statement that it will continue to deliver cancer and diabetes medicines to patients in Russia.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs